JP2012524029A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524029A5
JP2012524029A5 JP2012505008A JP2012505008A JP2012524029A5 JP 2012524029 A5 JP2012524029 A5 JP 2012524029A5 JP 2012505008 A JP2012505008 A JP 2012505008A JP 2012505008 A JP2012505008 A JP 2012505008A JP 2012524029 A5 JP2012524029 A5 JP 2012524029A5
Authority
JP
Japan
Prior art keywords
peptide
seq
clusterin
cargo molecule
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012505008A
Other languages
English (en)
Other versions
JP5861242B2 (ja
JP2012524029A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2010/000566 external-priority patent/WO2010118521A1/en
Publication of JP2012524029A publication Critical patent/JP2012524029A/ja
Publication of JP2012524029A5 publication Critical patent/JP2012524029A5/ja
Application granted granted Critical
Publication of JP5861242B2 publication Critical patent/JP5861242B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (16)

  1. クラステリンと特異的に結合することができる、配列番号1又は配列番号2で示したアミノ酸配列を含むペプチド。
  2. 配列番号1又は配列番号2で示した配列と少なくとも75%同一であるアミノ酸配列を含み、クラステリンと特異的に結合することができるペプチド。
  3. 配列番号1又は配列番号2で示したアミノ酸配列からなるペプチド。
  4. カーゴ分子に連結している、請求項1から3のいずれか1項に記載のペプチド。
  5. カーゴ分子が、酵素、イメージング部分、放射性同位体又は細胞傷害性薬剤を含む、請求項に記載のペプチド。
  6. カーゴ分子がイメージング部分を含む、請求項に記載のペプチド。
  7. イメージング部分が、放射標識、フルオロフォア、近赤外蛍光色素又は磁気ナノ粒子を含む、請求項に記載のペプチド。
  8. 分子イメージング、又はクラステリンが上方制御されている病状の検出のための、請求項1からのいずれか一項に記載のペプチドの使用。
  9. 腫瘍の分子イメージングのための、請求項に記載の使用。
  10. 分子イメージングが、光学イメージング、陽電子放出断層撮影、単一光子放射型コンピュータ断層撮影法、又は磁気共鳴画像である、請求項に記載の使用。
  11. 病状が癌である、請求項に記載の使用。
  12. 腫瘍細胞の検出のためのカーゴ分子に連結したペプチドを含む薬剤の使用であって、
    前記ペプチドがクラステリンと特異的に結合でき、かつ前記ペプチドが配列番号4に記載のアミノ酸配列を含む、使用。
  13. 前記ペプチドが請求項1から3のいずれか1項に記載のペプチドであって、かつ前記カーゴ分子がイメージング部分を有する、請求項12に記載の使用。
  14. 腫瘍細胞の上皮間葉移行を検出するための、クラステリンに特異的に結合でき、カーゴ分子に連結したペプチドを含む薬剤の使用。
  15. 前記ペプチドがクラステリンと特異的に結合することができ、かつ前記ペプチドが配列番号4に記載のアミノ酸配列を含む、請求項14に記載の使用。
  16. 前記ペプチドが請求項1から3のいずれか1項に記載のペプチドである、請求項15に記載の使用。
JP2012505008A 2009-04-17 2010-04-15 クラステリンのペプチドリガンド及びその使用 Active JP5861242B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20291009P 2009-04-17 2009-04-17
US61/202,910 2009-04-17
PCT/CA2010/000566 WO2010118521A1 (en) 2009-04-17 2010-04-15 Peptide ligands for clusterin and uses thereof

Publications (3)

Publication Number Publication Date
JP2012524029A JP2012524029A (ja) 2012-10-11
JP2012524029A5 true JP2012524029A5 (ja) 2013-05-30
JP5861242B2 JP5861242B2 (ja) 2016-02-16

Family

ID=42982086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505008A Active JP5861242B2 (ja) 2009-04-17 2010-04-15 クラステリンのペプチドリガンド及びその使用

Country Status (6)

Country Link
US (1) US8629240B2 (ja)
EP (1) EP2419440B1 (ja)
JP (1) JP5861242B2 (ja)
AU (1) AU2010237569B2 (ja)
CA (1) CA2756570C (ja)
WO (1) WO2010118521A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010324506B2 (en) 2009-11-24 2015-02-26 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
US9822170B2 (en) 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
CN110312549B (zh) * 2016-12-19 2021-06-29 莫尔豪斯医学院 用于通过抑制外泌体释放来治疗疾病的组合物和方法
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012558A1 (en) * 1997-09-10 1999-03-18 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
WO1999066046A1 (fr) * 1998-06-12 1999-12-23 Aventis Pasteur Mimotopes du virus hiv
US6348185B1 (en) * 1998-06-20 2002-02-19 Washington University School Of Medicine Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20050208558A1 (en) * 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
ITRM20040098A1 (it) * 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
US8044179B2 (en) * 2005-09-13 2011-10-25 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
WO2008049239A1 (en) * 2006-10-27 2008-05-02 Mount Sinai Hospital Endometrial biomarkers

Similar Documents

Publication Publication Date Title
Lu et al. Highly sensitive diagnosis of small hepatocellular carcinoma using pH-responsive iron oxide nanocluster assemblies
Dessale et al. Nanotechnology: a promising approach for cancer diagnosis, therapeutics and theragnosis
Gangadaran et al. Current perspectives on in vivo noninvasive tracking of extracellular vesicles with molecular imaging
Sun et al. Self-illuminating 64Cu-doped CdSe/ZnS nanocrystals for in vivo tumor imaging
Jiang et al. Multiple-armed tetrahedral DNA nanostructures for tumor-targeting, dual-modality in vivo imaging
JP2013532126A5 (ja)
Neves et al. Assessing responses to cancer therapy using molecular imaging
Doubrovin et al. Multimodality in vivo molecular-genetic imaging
Park et al. Theranostic probe based on lanthanide‐doped nanoparticles for simultaneous in vivo dual‐modal imaging and photodynamic therapy
Abdukayum et al. Gadolinium complexes functionalized persistent luminescent nanoparticles as a multimodal probe for near-infrared luminescence and magnetic resonance imaging in vivo
Kircher et al. Noninvasive cell-tracking methods
MX362675B (es) Antagonistas de receptores de péptido liberadores de gastrina para la detección, diagnóstico y tratamiento de cáncer positivo a receptores de péptido liberadores de gastrina.
Kamkaew et al. Quantum dot–NanoLuc bioluminescence resonance energy transfer enables tumor imaging and lymph node mapping in vivo
JP2012524029A5 (ja)
Lu et al. Bacteria‐instructed in situ aggregation of AuNPs with enhanced photoacoustic signal for bacterial infection bioimaging
JP2014521661A5 (ja)
EP3499233A3 (en) Fluorescent silica-based nanoparticles
Du et al. GX1-conjugated poly (lactic acid) nanoparticles encapsulating Endostar for improved in vivo anticolorectal cancer treatment
A Sasser et al. Bacterial infection probes and imaging strategies in clinical nuclear medicine and preclinical molecular imaging
Gries et al. Multiscale selectivity and in vivo biodistribution of NRP-1-targeted theranostic AGuIX nanoparticles for PDT of glioblastoma
Heryanto et al. In vivo molecular imaging of cancer stem cells
López‐Colón et al. Aptamers: turning the spotlight on cells
Priem et al. Fluorescent nanoparticles for the accurate detection of drug delivery
Zhang et al. NIRF Optical/PET Dual‐Modal Imaging of Hepatocellular Carcinoma Using Heptamethine Carbocyanine Dye
Wang et al. Aptamer-based molecular imaging